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A procedure is suggested for measuring acetylcholinesterase and butyrylcholinesterase activities in 
human whole blood using acetylthiocholine as a substrate and ethopropazine as a selective inhibitor of 
butyrylcholinesterase. The procedure is suitable for screening cholinesterase activities in routine and/or 
field tests.
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The inhibition of acetylcholinesterase (EC 
3.1.1.7; AChE) and butyrylcholinesterase (EC 
3.1.1.8; BChE) in human whole blood is an indicator 
of the absorption of cholinesterase inhibitors such 
as the highly toxic organophosphorus compounds. 
Erythrocyte AChE activity in human blood reflects 
the status of synaptic AChE, which is the target 
enzyme of anticholinesterases. However, most 
organophosphorus compounds inhibit plasma BChE 
faster than erythrocyte AChE, and the inhibition of 
plasma BChE is therefore a more sensitive indicator 
of the absorption of these agents. Consequently, more 
information about the exposure of an individual to 
anticholinesterases can be obtained if both AChE and 
BChE activities are determined.
Human blood contains BChE in plasma and AChE 
which is bound to the erythrocyte membrane. In order 
to determine the activity of each enzyme, erythrocytes 
and plasma have either to be separated or one has to 
apply selective substrates and/or inhibitors to assay 
only one enzyme in the presence of the other. Each 
approach has its advantages and disadvantages, and 
any assay of cholinesterases in whole blood is subject 
to some intrinsic error(s).
A widely used method for determining 
cholinesterase activities is the spectrophotometric 
method of Ellman et al. (1) with thiocholine esters as 
substrates and DTNB as the thiol reagent. Over the past 
ten years this method has repeatedly been modified in 
order to meet requirements for different applications 
(cf 2). Several authors described procedures that 
might enable assessment of both AChE and BChE 
enzymes in whole blood. Meuling et al. (3) used 
propionylthiocholine as substrate, and measured 
the enzyme activity in the presence and absence of 
the selective BChE inhibitor ethopropazine [10-(2-
diethylaminopropyl) phenothiazine hydrochloride] by 
recording the absorbances of the reaction product 
at 415 and 450 nm. The activities of AChE and 
BChE were calculated from the differences between 
activities measured in the presence and absence 
of ethopropazine. These measurements require an 
instrument that can simultaneously measure the 
absorbance at two wavelengths. A group of Swiss 
authors (cf. 2) suggested acetylthiocholine (ATCh) and 
butyrylthiocholine (BTCh) as substrates to determine 
both AChE and BChE activities in whole blood. ATCh 
is a substrate for both enzymes, but the authors 
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considered BTCh primarily as a BChE substrate. 
Worek et al. (4) suggested a method for determining 
AChE activities in whole blood by measuring the 
activity with ATCh in the presence of ethopropazine. 
These authors measured BChE activities separately 
in plasma.
In this paper, we suggest a procedure that does 
not require separation of plasma from erythrocytes. 
The procedure is based on the method of Worek et 
al. (4), but it requires only one substrate (ATCh) and 
ethopropazine as a selective BChE inhibitor in order 
to evaluate both AChE and BChE activities in human 
whole blood.
GENERAL OUTLINE OF THE PROCEDURE
The activities of AChE and BChE are measured in 
whole blood with ATCh as substrate in the absence 
(vT) and in the presence (vE) of ethopropazine. The vT 
activity is the sum of both AChE and BChE activities. 
The vE should be the AChE activity, if ethopropazine is 
a sufficiently selective BChE inhibitor. The difference 
between vT and vE should  therefore be the BChE 
activity.
To verify the suggested procedure, cholinesterase 
activities were measured with ATCh and BTCh as 
substrates in whole blood, in plasma, and in erythrocytes 
in the absence and presence of ethopropazine. The 
inhibitor was racemic ethopropazine.
EXPERIMENTAL
The enzyme source was heparinised whole blood 
from 10 healthy adults (4 female, 6 male). An aliquot 
of each blood sample was centrifuged to separate 
plasma from erythrocytes. The erythrocytes were 
washed with buffer to remove residual plasma, and 
diluted with buffer to the volume of the whole blood. 
Blood samples were taken from individuals who had 
the usual (UU) plasma BChE phenotype. The BChE 
had previously been phenotyped by measuring its 
activity with benzoylcholine as substrate and dibucaine 
as a differentiating inhibitor (5, 6). The dibucaine 
numbers were 80-82.
Activities were measured at 436 nm in 0.1 mol L-1 
phosphate buffer, pH=7.4 at 37 °C with DTNB (5,5’-
dithiobis-2-nitrobenzoic acid) as the thiol reagent (cf. 
7 and 8 for details). The final concentrations during 
enzyme assay were: DTNB 0.30 mmol L-1, ATCh or 
BTCh 1.0 mmol L-1, and ethopropazine 20 µmol L-1. 
Final dilutions of whole blood, washed erythrocytes 
and plasma ranged between 120-fold and 600-fold, 
depending on the enzyme activities. The activities 
were calculated using the molar absorption coefficient 
11280 L mol-1 cm-1 for the dianion of 5-thio-2-
nitrobenzoic acid (9). Activities were corrected for 
spontaneous substrate hydrolysis.
In the method described by Ellman et al. (1), 
activities are measured at 412 nm. At that wavelength 
haemoglobin has a high absorption which decreases 
the sensitivity of measurements, particularly for 
haemolysed blood samples and at low enzyme 
activities (cf. 4). For that reason we followed the 
suggestion of Worek et al. (4) and measured activities 
at 436 nm.
RESULTS AND DISCUSSION
Ethopropazine is a potent BChE inhibitor and a poor 
AChE inhibitor. Due to this property, ethopropazine is 
used to selectively inhibit the BChE activity in samples 
where both AChE and BChE are present (3, 4, 8, 10, 
11). The recommended ethopropazine concentration 
for this differential inhibition is 20 µmol L-1, which was 
also used in the present study.
Table 1 shows the inhibition of ATCh hydrolysis 
by ethopropazine in 10 whole blood samples and in 
washed erythrocytes. The inhibition of ATCh hydrolysis 
by ethopropazine in the usual (UU) plasma BChE is 
known from previous studies, and it amounts to 98 
% (8).
Table 1  Inhibition of AChE and BChE by ethopropazine measured with 












4.8 ± 1.6 2.5-7.7
We suggest ATCh as the substrate for measuring 
both AChE and BChE activities, because ATCh is well 
hydrolysed by both enzymes which is not the case with 
BTCh, as shown in Table 2.
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Table 2  Mean activities (v) of AChE and BChE measured in 10 blood 
samples with acetylthiocholine (ATCh) and butyrylthiocholine 
(BTCh) as substrates in the absence of ethopropazine. Activities 
in whole blood and washed erythrocytes are expressed per mL 
































Table 3 shows the rates of ATCh hydrolysis in 10 
whole blood samples in the absence (vT) and presence 
(vE) of ethopropazine. The measured vE rates should 
correspond to the AChE activity. However, AChE is 
slightly inhibited by ethopropazine (cf. Table 1). The 
vE were therefore corrected for the degree of inhibition 
by ethopropazine, vE,corr. Corrections were done using 
the mean percent of inhibition (4.8 %) given in Table 1. 
The calculated difference between vT and vE,corr  should 
be the activity of plasma BChE in whole blood.
Table 3  Mean activities (v) of AChE and BChE measured in 10 whole 
blood samples with acetylthiocholine as substrate in the 
presence and absence of ethopropazine (Etho). Activities are 
expressed per mL of whole blood or mL of plasma (indicated 
with an asterisk*)
Enzyme
v ± SD / 
µmol min-1 mL-1
vT = activity without Etho 8.60 ± 0.77
vE = activity in the presence of Etho 6.71 ± 0.75
vE, corr = activity corrected for the 
inhibition of AChE by Etho
7.03 ± 0.79
*vP, calc = calculated BChE activity in 
plasma from vT and vE, corr
2.90 ± 0.61
*vP, meas = measured BChE activity in 
plasma (cf. Table 2)
3.09 ± 0.67
The calculated plasma BChE activities (Table 3) 
were compared with the BChE activities measured 
in plasma (Table 2). The volume of plasma in whole 
blood depends on the haematocrit. The haematocrit 
mean values were 0.49 and 0.41 for male and female 
subjects respectively (own data on 8 male and 8 
female individuals). Applying these haematocrits, 
BChE activities were expressed as activities per 
millilitre of plasma in order to have the calculated 
BChE activities in Table 3 (vP,calc) expressed in the same 
unit as the measured activities in Table 2 (vP,meas). It 
follows from Table 3 that the vP,calc  is on average 6 % 
lower than vP,meas. This difference is not significant, as 
the mean values of these two activities overlap within 
one standard error. We therefore consider that vP,meas 
and vP,calc are in agreement. This in turn shows that 
BChE activities in whole blood can be determined as 
suggested in this paper.
In the above protocol no correction is suggested 
for the 2 % activity of the usual (UU) BChE which 
is not inhibited by ethopropazine, because it makes 
no significant contribution to the AChE activity 
measured in presence of ethopropazine. In Caucasian 
populations, 95 % of individuals have the usual (UU) 
phenotype (5, 12, 13). However, individuals with 
the atypical (AA) phenotype and heterozygotes of 
the A variant are less inhibited (74-87 %) than the 
UU phenotype (8) in which case the error due to 
incomplete inhibition of BChE by ethopropazine will 
be greater. Individuals with the AA phenotype have 
in Caucasian populations a frequency of less than 
1 % (12).
In conclusion, we consider the procedure 
described above as suitable for screening AChE and 
BChE activities in human whole blood in routine 
and/or field tests. The procedure is also suitable for 
measuring activities in haemolysed blood samples.
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Saetak
AKTIVNOST KOLINESTERAZA U PUNOJ LJUDSKOJ KRVI MJERENA ACETILTIOKOLINOM 
KAO SUPSTRATOM I ETOPROPAZINOM KAO SELEKTIVNIM INHIBITOROM KOLINESTERAZE 
U PLAZMI
Predloen je postupak mjerenja aktivnosti acetilkolinesteraze i butirilkolinesteraze u punoj humanoj krvi. 
Aktivnost se mjeri acetiltiokolinom kao supstratom u prisutnosti i odsutnosti etopropazina. Etopropazin je 
selektivni inhibitor butirilkolinesteraze te aktivnost mjerena u prisutnosti etopropazina predstavlja aktivnost 
acetilkolinesteraze. Razlika aktivnosti mjerenih u odsutnosti i prisutnosti etopropazina predstavlja aktivnost 
butirilkolinesteraze. Predloeni je postupak prikladan za rutinska mjerenja i/ili mjerenja na terenu.
KLJUÈNE RIJEÈI: acetilkolinesteraza, butirilkolinesteraza, mjerenje aktivnosti u punoj krvi, postupak 
mjerenja u punoj krvi
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